Get Started

LBRX

NASD LB Pharmaceuticals, Inc.
Oct 31, 2026 · 4:54 AM ET EOD Market Closed

$39.70 ↑ +0.00 (+0.00%) Trading Up from the previous close of $39.70, $1.54 below the day’s high of $41.24

YTD change
+78.35%
vs 20-day SMA
+6.41%
vs 200-day SMA
+22.26%

Price ranges

Previous day
$39.13 $41.24
open $40.10 close $39.70
-$0.40 (-1.00%)
Today
$39.13 $41.24
$39.70
Past week
$38.26 $41.05
from $39.42 now $39.70
+$0.28 (+0.71%)
Past month
$33.13 $41.58
from $37.28 now $39.70
+$2.42 (+6.49%)
This year
$18.43 $50.16
from $22.26 now $39.70
+$17.44 (+78.35%)

Price & Performance

+8.27 (+26.31%) / 6M

$25.22$33.91$42.59$51.28May 1Aug 3Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 20.9% away from all-time highs of $50.16
  • LBRX is up 78% since the beginning of the year
  • LBRX is up 144% over the past 12 months
  • LBRX is up 6% over the past 1 month
  • 36% of all LBRX investors are betting against LBRX

LBRX reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +146.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-1.71
Earnings momentum -5.5% Quarterly EPS growth
Quarterly change -5.5%

Valuation

P/E ratio N/A
Enterprise value $887.5M
Beta 0.78

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$327.8M
Debt$5.2K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $1.3B

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,417.54 +3.19%
JNJ Johnson & Johnson $273.20 -0.73%
ABBV AbbVie, Inc. $294.89 +1.41%
MRK Merck & Co., Inc. $149.52 +2.18%
RHHBY Roche Holding Ltd Sponsored ADR $61.27 +0.82%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.